Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01455857 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT01455857: Completed Phase 3 study, sponsored by Intarcia Therapeutics.
NCT01455857 is a Phase 3 study that has completed, run by Intarcia Therapeutics. The registered enrollment target is 460 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01455857, a Phase 3 study, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.
Primary Outcome
39-week Treatment Period
Interventions
- DRUG ITCA 650
- OTHER ITCA placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
What the finished NCT01455857 record still lists
NCT01455857 is an interventional study that assigns participants to a tested intervention. The registered 460 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 2 interventions - of which ITCA 650 is the first listed.
NCT01455857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01455857 about?
NCT01455857 is a clinical study titled "A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes". Phase 3 study to examine whether treatment with ITCA-650 60 mcg/day or 40 mcg/day is superior to placebo when added to current therapy in reducing HbA1c in patients with type 2 diabetes.
What is the current status of trial NCT01455857?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants. The study started on 2013-03. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01455857?
The interventions under investigation include: ITCA 650 (DRUG), ITCA placebo (OTHER).
Who is sponsoring clinical trial NCT01455857?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01455857's enrollment target sits among peer trials
460 823rd of 2000 higher than 1,174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
- NCT04621279 · 460 participants
Cool Prime Comparative Effectiveness Study for Mild HIE
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia